For the fiscal year ending December 2025, consolidated net sales were JPY 165,742 million (up 0.1% YoY), operating income was JPY 14,923 million (down 40.0% YoY), and net income attributable to owners of the parent was JPY 3,656 million (down 63.7% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4967-20260210-01.pdf","jir_short_summary":"For the fiscal year ending December 2025, consolidated net sales were JPY 165,742 million (up 0.1% YoY), operating income was JPY 14,923 million (down 40.0% YoY), and net income attributable to owners of the parent was JPY 3,656 million (down 63.7% YoY).","jir_summary":"### Overview of Business Performance\nConsolidated net sales for the fiscal year ending December 2025 were JPY 165,742 million (up 0.1% YoY), almost flat; however, operating income fell significantly to JPY 14,923 million (down 40.0% YoY), ordinary income declined to JPY 16,995 million (down 36.7% YoY), and net income attributable to owners of the parent sharply decreased to JPY 3,656 million (down 63.7% YoY). The main factors included the recording of an extraordinary loss (impairment loss) of JPY 14,645 million related to the new Sendai plant and the Thailand plant, as well as suspension of advertising and compensation costs triggered by voluntary recalls of red yeast rice-related products. Domestic operations showed recovery in sales due to new product launches and resurgence in inbound demand, but sales declined owing to the termination of e-commerce operations. International operations saw increased sales in the U.S. and Southeast Asia, offset by decreased demand in the Chinese market.\n\n### Financial Position, Cash Flows, and Future Outlook\nTotal assets increased to JPY 275,329 million compared to the previous fiscal year, while net assets decreased to JPY 211,008 million, causing the equity ratio to decline to 76.3%. Cash flows from operating activities improved significantly to JPY 25,590 million, cash outflows from investing activities amounted to JPY 154 million, and cash outflows from financing activities were JPY 7,921 million. For the fiscal year ending December 2026, net sales are forecasted at JPY 173,000 million (up 4.4% YoY), but operating income is expected to decrease to JPY 12,500 million (down 16.2% YoY) due to increased advertising expenses and higher costs related to the operation of new plants and research facilities. The company has launched a new three-year medium-term management plan aimed at restoring trust and achieving sustainable growth. Dividends for the fiscal year ending December 2026 are planned at JPY 106 per share.","jir_financial_highlights":"Net Sales: JPY 165,742 million (Up 0.1% YoY)\nOperating Income: JPY 14,923 million (Down 40.0% YoY)\nOrdinary Income: JPY 16,995 million (Down 36.7% YoY)\nNet Income Attributable to Owners of Parent: JPY 3,656 million (Down 63.7% YoY)\nDividend per Share: JPY 104 (Fiscal Year Ending December 2025) (Up JPY 2 YoY)\nNumber of Issued Shares (Common Stock): 78,050,000 shares (Unknown)\nNumber of Treasury Shares: 3,711,236 shares (Unknown)\nCash Flows from Operating Activities: JPY 25,590 million (Increased YoY (JPY 11,246 million \u2192 JPY 25,590 million))\nExtraordinary Loss (Impairment Loss): JPY 14,645 million (Newly Recorded)","jir_category":"","jir_hashtags":"#KobayashiPharmaceutical, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: JPY 165,742 million (Up 0.1% YoY)\nOperating Income: JPY 14,923 million (Down 40.0% YoY)\nNet Income Attributable to Owners of Parent: JPY 3,656 million (Down 63.7% YoY)","jir_meta_title":"Kobayashi Pharmaceutical Co., Ltd. Fiscal Year Ending December 2025 Financial Summary\uff5cNet Sales JPY 165,742 Million, Operating Income Down 40.0%","jir_meta_description":"Financial summary of Kobayashi Pharmaceutical Co., Ltd. for the fiscal year ending December 2025. Net sales were JPY 165,742 million (up 0.1% YoY), operating income was JPY 14,923 million (down 40.0% YoY), and net income was JPY 3,656 million (down 63.7% YoY). Sales growth expected but earnings decline forecast for fiscal year ending December 2026.","jir_og_title":"Kobayashi Pharmaceutical Announces Financial Summary for Fiscal Year Ending December 2025","jir_og_description":"Net sales of JPY 165,742 million and operating income of JPY 14,923 million. Significant profit decline due to recording of extraordinary losses. Sales growth anticipated in 2026 but earnings are expected to decrease.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Forecast for Fiscal Year Ending December 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[165600,165742,173000],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Forecast for Fiscal Year Ending December 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[24860,14923,12500],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Forecast for Fiscal Year Ending December 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[10067,3656,10000],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales (Million JPY) Fiscal Year Ending December 2025\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Operations\\\",\\\"International Operations\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[122920,48415,6581],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#28a745\\\",\\\"#ffc107\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"profit_margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Margin Comparison (%)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Margin\\\",\\\"data\\\":[15.0,9.0],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#dc3545\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true,\\\"max\\\":20}}}}\"}, {\"jir_chart_id\": \"dividend_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Dividend per Share Trend (JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\",\\\"Forecast for Fiscal Year Ending December 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Dividend\\\",\\\"data\\\":[102,104,106],\\\"borderColor\\\":\\\"#17a2b8\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-27077","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n